What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to present a revised reconciliation of AbbVie's reported GAAP (Generally Accepted Accounting Principles) financial results to its non-GAAP financial results for the periods ending December 31, 2021, including both quarter-to-date and year-to-date figures.

Are there any new financial results or guidance provided in this filing?

No, this 8-K filing does not provide any new operational results, earnings announcements, or forward-looking guidance. Its sole purpose is to update the reconciliation of historical non-GAAP financial measures.

Why is a revised reconciliation of non-GAAP results important for investors?

A revised non-GAAP reconciliation is important for investors because non-GAAP measures are often used by management to provide a view of the company's performance excluding certain items that may not be indicative of ongoing operational trends. Understanding the adjustments made to derive these non-GAAP figures allows investors to better assess the company's underlying business performance, compare results across periods, and evaluate the company's financial health.

Where can I find the detailed revised reconciliation information?

The detailed revised reconciliation of reported GAAP and non-GAAP results for the year ended December 31, 2021, can be found in Exhibit 99.1, which is included as part of this Current Report on Form 8-K.

ABBV 8-K: Earnings & Results

Summary

AbbVie Inc. filed a Form 8-K on April 21, 2022, primarily to provide investors with a revised reconciliation of its reported GAAP and non-GAAP financial results for the periods ended December 31, 2021 (both quarter-to-date and year-to-date). This filing indicates a retroactive adjustment to how the company presents its performance metrics beyond generally accepted accounting principles. While this 8-K doesn't contain new operational or strategic announcements, the revised non-GAAP reconciliation is significant for investors who rely on these metrics for a clearer understanding of underlying business performance, excluding certain items like stock-based compensation, amortization, and other discrete items. Investors should review Exhibit 99.1 to understand the specific adjustments made and their impact on the reported non-GAAP figures, as these adjustments can influence comparisons to prior periods and to industry peers.

Key Highlights

1Filing of an 8-K on April 21, 2022, by AbbVie Inc. (ABBV).
2The primary purpose is to provide revised financial information.
3Exhibit 99.1 includes a revised reconciliation of GAAP to non-GAAP results for year-end 2021.
4Reconciliation covers both quarter-to-date and year-to-date periods for the year ended December 31, 2021.
5This filing does not disclose new operational results or forward-looking guidance.
6The filing includes standard XBRL formatted cover page as Exhibit 104.

AbbVie Inc. 8-K Report, Financial Results (Apr 21, 2022)

Summary

Key Highlights

Frequently Asked Questions